A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).

R. Furman, Richard; C. Barrientos, Jacqueline; P. Sharman, Jeff; de Vos, Sven; P. Leonard, John; Coutré, Steven; T. Schreeder, Marshall; D. Wagner‐Johnston, Nina; E. Boyd, Thomas; Fowler, Nathan; W. Flinn, Ian; V. Boccia, Ralph; Holes, Leanne; J. Lannutti, Brian; Johnson, Dave; M. Jahn, Thomas; L. Miller, Langdon

doi:10.1200/jco.2012.30.15_suppl.6518

Public

A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).

Published in Journal of Clinical Oncology • May 20, 2012

Authors:

Richard R. Furman

Jacqueline C. Barrientos

Jeff P. Sharman

Abstract

6518^ Background: PI3Kδ is expressed in cells of hematopoietic origin where it regulates the survival and proliferation of malignant B-cells. GS-1101 is an orally bioavailable, small-molecule inhibitor that selectively targets PI3Kδ and is highly active in patients with hematologic malignancies. Met...

Subject

Medicine

Ofatumumab

Gastroenterology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!